Tags

Type your tag names separated by a space and hit enter

The use of anti-spasmodics in the treatment of irritable bowel syndrome: focus on otilonium bromide.
Eur Rev Med Pharmacol Sci. 2012 Jan; 16(1):25-37.ER

Abstract

OBJECTIVE

Aim of this review is to summarize the studies carried out, with particular interest in those who dealt with otilonium bromide in treatment of IBS. Irritable bowel syndrome (IBS).

DISCUSSION

IBS is a frequent gastrointestinal disease, characterized by a combination of several symptoms including abdominal pain or discomfort, flatulence and problems related to bowel habits (constipation and/or diarrhea). It affects about 15% of the western population, with a negative impact on the quality of life and also on health care costs. Face to such important complexity and negative impact, therapeutic options are still very limited and most of the pharmacological compounds mostly validated for short term use, are only partially controlling symptoms. Among those, anti-spasmodics are commonly used in clinical settings. Despite a discrete literature in support of these drugs, systematic collections of clinical evidence to support the use of anti-spasmodics and in particular the use of otilonium bromide in course of IBS are scarce.

RESULTS AND CONCLUSION

Otilonium bromide is a systemically poorly absorbed antispasmodic, which has shown clear efficacy compared to placebo, in controlling symptoms related to IBS. Otilonium bromide was effective also in comparison to other drugs, such as pinaverium bromide and mebeverine, with a favorable tolerability profile. Further studies are necessary to better define duration of treatment and maximum therapeutic dose.

Authors+Show Affiliations

Department of Internal Medicine, Division of Gastroenterology, School of Medicine, Catholic University of the Sacred Heart, Rome, Italy.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

22338545

Citation

Forte, E, et al. "The Use of Anti-spasmodics in the Treatment of Irritable Bowel Syndrome: Focus On Otilonium Bromide." European Review for Medical and Pharmacological Sciences, vol. 16, no. 1, 2012, pp. 25-37.
Forte E, Pizzoferrato M, Lopetuso L, et al. The use of anti-spasmodics in the treatment of irritable bowel syndrome: focus on otilonium bromide. Eur Rev Med Pharmacol Sci. 2012;16(1):25-37.
Forte, E., Pizzoferrato, M., Lopetuso, L., & Scaldaferri, F. (2012). The use of anti-spasmodics in the treatment of irritable bowel syndrome: focus on otilonium bromide. European Review for Medical and Pharmacological Sciences, 16(1), 25-37.
Forte E, et al. The Use of Anti-spasmodics in the Treatment of Irritable Bowel Syndrome: Focus On Otilonium Bromide. Eur Rev Med Pharmacol Sci. 2012;16(1):25-37. PubMed PMID: 22338545.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The use of anti-spasmodics in the treatment of irritable bowel syndrome: focus on otilonium bromide. AU - Forte,E, AU - Pizzoferrato,M, AU - Lopetuso,L, AU - Scaldaferri,F, PY - 2012/2/18/entrez PY - 2012/2/18/pubmed PY - 2012/3/13/medline SP - 25 EP - 37 JF - European review for medical and pharmacological sciences JO - Eur Rev Med Pharmacol Sci VL - 16 IS - 1 N2 - OBJECTIVE: Aim of this review is to summarize the studies carried out, with particular interest in those who dealt with otilonium bromide in treatment of IBS. Irritable bowel syndrome (IBS). DISCUSSION: IBS is a frequent gastrointestinal disease, characterized by a combination of several symptoms including abdominal pain or discomfort, flatulence and problems related to bowel habits (constipation and/or diarrhea). It affects about 15% of the western population, with a negative impact on the quality of life and also on health care costs. Face to such important complexity and negative impact, therapeutic options are still very limited and most of the pharmacological compounds mostly validated for short term use, are only partially controlling symptoms. Among those, anti-spasmodics are commonly used in clinical settings. Despite a discrete literature in support of these drugs, systematic collections of clinical evidence to support the use of anti-spasmodics and in particular the use of otilonium bromide in course of IBS are scarce. RESULTS AND CONCLUSION: Otilonium bromide is a systemically poorly absorbed antispasmodic, which has shown clear efficacy compared to placebo, in controlling symptoms related to IBS. Otilonium bromide was effective also in comparison to other drugs, such as pinaverium bromide and mebeverine, with a favorable tolerability profile. Further studies are necessary to better define duration of treatment and maximum therapeutic dose. SN - 1128-3602 UR - https://www.unboundmedicine.com/medline/citation/22338545/The_use_of_anti_spasmodics_in_the_treatment_of_irritable_bowel_syndrome:_focus_on_otilonium_bromide_ L2 - http://www.diseaseinfosearch.org/result/3876 DB - PRIME DP - Unbound Medicine ER -